Alexei F Kisselev Selected Research

carfilzomib

1/2022	A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax.
12/2021	Site-Specific Proteasome Inhibitors.
1/2021	Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein.
10/2018	An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.
2/2017	Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation.
8/2015	The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
5/2011	Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alexei F Kisselev Research Topics

Disease

11	Multiple Myeloma 01/2022 - 05/2011
11	Neoplasms (Cancer) 01/2021 - 03/2006
3	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2021 - 01/2012
2	Cockayne Syndrome (Syndrome, Cockayne) 06/2006 - 05/2003
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021
1	Genetic Translocation (Chromosomal Translocation) 01/2021
1	Triple Negative Breast Neoplasms 02/2017
1	Hematologic Neoplasms (Hematological Malignancy) 03/2016
1	B-Cell Lymphoma (Lymphoma, B Cell) 08/2015
1	Autoimmune Diseases (Autoimmune Disease) 12/2014
1	Lung Neoplasms (Lung Cancer) 04/2014
1	Human Influenza (Influenza) 08/2012
1	Reperfusion Injury 01/2012
1	Leukemia 07/2011
1	Inborn Genetic Diseases (Disease, Hereditary) 05/2003
1	Xeroderma Pigmentosum (Kaposi's Disease) 05/2003

Drug/Important Bio-Agent (IBA)

11	Proteasome InhibitorsIBA 01/2022 - 03/2006
10	Bortezomib (Velcade)FDA Link 01/2022 - 05/2011
7	carfilzomibIBA 01/2022 - 05/2011
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2003
5	Proteasome Endopeptidase Complex (Proteasome)IBA 02/2017 - 06/2006
2	ixazomibIBA 12/2021 - 10/2018
2	TrypsinIBA 04/2014 - 02/2013
2	UbiquitinIBA 12/2013 - 06/2006
2	Chymotrypsin FDA Link 05/2011 - 03/2006
1	marizomibIBA 12/2021
1	azido- Phe- Leu- Leu- 4- aminomethyl- Phe- methyl vinyl sulfoneIBA 08/2015
1	ibrutinibIBA 08/2015
1	Agammaglobulinaemia Tyrosine KinaseIBA 08/2015
1	I-kappa B Proteins (I kappa B)IBA 08/2015
1	Peptide Hydrolases (Proteases)FDA Link 04/2014
1	ATP dependent 26S protease (26S proteasome)IBA 12/2013
1	EpitopesIBA 08/2012
1	Peptides (Polypeptides)IBA 06/2007
1	DDBIBA 05/2003

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 01/2020
1	Radiotherapy 01/2020
1	Therapeutics 03/2006